The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
30 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $12,455,263 in first-year total cost, median $242,793.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-A (11)]8
- Special Emphasis Panel[ZRG1 RPHB-Y (12)]8
- Special Emphasis Panel[ZRG1 ETTN-C (10)]5
- Special Emphasis Panel[ZRG1 ETTN-P (13)]5
- Special Emphasis Panel[ZRG1 ETTN-G (12)]2
Most frequent institutions
- ADM DIAGNOSTICS, INC.2
- CASSAVA SCIENCES, INC2
- HEARTHSTONE ALZHEIMER CARE, LTD2
- PHOTOZIG, INC.2
- ACTIVAS DIAGNOSTICS, LLC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | Solid oral dosage form and chronic tox for PTI-1252R44AG056166-03 | BURNS, LINDSAY H | CASSAVA SCIENCES, INC, TX | $2,896,320 | ZRG1 |
| 2018 | Tau oligomer platform validation using lead series candidate in htau mice2R44AG053150-03 | MOE, JAMES G. | OLIGOMERIX, INC, NY | $999,248 | ZRG1 |
| 2018 | AD-MS Chips for Biofluids-Based Diagnosis of Alzheimer's Disease2R44AG046025-03 | WANG, DAOJING | NEWOMICS, INC, CA | $749,999 | ZRG1 |
| 2018 | Home-based Sleep Technology for MCI and Alzheimer's Disease Monitoring1R44AG059536-01 | ABEDI, ALIHAYES, MARIE J | ACTIVAS DIAGNOSTICS, LLC, ME | $500,000 | ZRG1 |
| 2018 | First-in-human study of MW151, a novel drug targeting neuroinflammation1R44AG060846-01 | SHIFRIN, VICTORWATTERSON, DANIEL MARTIN | IMMUNOCHEM THERAPEUTICS, LLC, MA | $499,320 | ZRG1 |
| 2018 | Deep Learning Gait Analytics for Primary Care1R43AG060855-01 | MORRIS, RICHARD | GAITIQ, LLC, TX | $459,656 | ZRG1 |
| 2018 | Microparticle Therapy for Cerebral Amyloid Angiopathy1R43AG059478-01 | KIRSCH, WOLFF M. | KARAMEDICA, INC., NC | $378,841 | ZRG1 |
| 2018 | A first-in-class orally active anti-TNF-alpha inhibitor to treat AD2R44AG044958-02 | GABBITA, SOMASUNDAR PRASADVARADARAJAN, SRIDHAR | P2D, INC., OH | $337,833 | ZRG1 |
| 2018 | Novel small molecules that target Alzheimer's disease by increasing spinogenesis and decreasing A-beta toxicity1R43AG058278-01A1 | SIMMON, VINCENT F. | SPINOGENIX, INC., CA | $314,511 | ZRG1 |
| 2018 | A mobile self-compassion intervention for Hispanic Dementia Caregivers1R43AG059327-01 | KAJIYAMA, BRUNO | PHOTOZIG, INC., CA | $293,661 | ZRG1 |
| 2018 | Somatostatin (SST)-GABAergic Interneuron Therapy for Alzheimer's Disease with ApoE41R44AG060873-01 | MAHLEY, ROBERT W.TONG, LESLIE | GABAERON, INC., CA | $292,422 | ZRG1 |
| 2018 | Multiple Ascending Dose clinical trial of PTI-125, a novel AD therapeutic candidate1R44AG060878-01 | BURNS, LINDSAY H | CASSAVA SCIENCES, INC, TX | $260,585 | ZRG1 |
| 2018 | Targeting Bioenergetic Flux for Alzheimer's Disease Management1R43AG060817-01 | MICHAELIS, ELIAS K | AEROBYX, LLC, KS | $225,001 | ZRG1 |
| 2018 | Device to measure circadian-effective light in Alzheimer's disease environments1R43AG060857-01 | PAGE, ERIK | ERIK PAGE AND ASSOCIATES, INC., CA | $225,000 | ZRG1 |
| 2018 | Technology-Enabled Therapy for Elders with Mild Cognitive Impairment and Co-morbid Insomnia1R43AG058334-01A1 | CHEN, HONGTU | ENVIRONMENT AND HEALTH GROUP, INC., MA | $224,844 | ZRG1 |
| 2018 | Care Assistant for Family Caregivers of Alzheimer Patients During Out of the Home Activities1R43AG058336-01A1 | ANDERSON, SHANE M. | KORONIS BIOMEDICAL TECHNOLOGIES CORPORAT, MN | $224,823 | ZRG1 |
| 2018 | Alzheimer's Amyloid and Tau Pathology Staging and Clinical Impact Prediction Using Multi-Modal MRI Pattern Classification1R43AG059540-01 | LUKIC, ANA S | ADM DIAGNOSTICS, INC., IL | $224,796 | ZRG1 |
| 2018 | LEAD IT! An App to Enable Persons with Early Stage Dementia to Lead Group Activities for Their Peers1R43AG059443-01 | SKRAJNER, MICHAEL JOHN | HEARTHSTONE ALZHEIMER CARE, LTD, MA | $224,673 | ZRG1 |
| 2018 | Identifying New Immunomodulatory Targets for Alzheimers and Other Neurodegenerative Diseases1R43AG060787-01 | DORANZ, BENJAMIN J | INTEGRAL MOLECULAR, PA | $210,918 | ZRG1 |
| 2018 | Multi-modal machine learning detection and tracking of traumatic brain injury neurodegeneration and its differentiation from Alzheimer's disease1R43AG060861-01 | LUKIC, ANA S | ADM DIAGNOSTICS, INC., IL | $208,181 | ZRG1 |
| 2018 | Diagnosis of Alzheimer's Disease and Prediction of Clinical Progression Using an Automated PET Image Analysis Tool1R44AG060798-01 | ULUG, AZIZ M | CORTECHS LABS, INC., CA | $150,000 | ZRG1 |
| 2018 | Supporting Social Engagement Through Technology for Older Adults With and Without MCI1R43AG059450-01 | MYERS, DILLONROGERS, WENDY A | POTLUCK, LLC, VA | $144,203 | ZRG1 |
| 2018 | Decide, Discover, and Do: An Intervention for Community-Dwelling Older Adults with Alzheimer's and Other Dementias1R43AG059442-01 | GORZELLE, GREGG | HEARTHSTONE ALZHEIMER CARE, LTD, MA | $120,930 | ZRG1 |
| 2017 | Progressing the Pre-clinical development of P8 for Alzheimer's Disease2R44AG043278-04 | DEWJI, NAZNEEN N | CENNA BIOSCIENCES, INC., CA | $750,000 | ZRG1 |
| 2017 | Functional integrated human-on-a-chip systems for Alzheimer's research1R44AG058330-01 | HICKMAN, JAMES JMORGAN, DAVIDSHULER, MICHAEL L | HESPEROS, LLC, FL | $454,315 | ZRG1 |
| 2017 | Mindfulness-based Cognitive Coping Mobile App Intervention for caregivers of individuals with Alzheimer’s Disease1R43AG058277-01 | KAJIYAMA, BRUNO | PHOTOZIG, INC., CA | $306,623 | ZRG1 |
| 2017 | New BDNF Nanoparticles for Early Treatment of Alzheimer's Disease1R44AG058343-01 | VITALIANO, FRANCOVITALIANO, GORDANA D. | EXQOR TECHNOLOGIES, INC., MA | $224,798 | ZRG1 |
| 2017 | Validation of a Performance Based Measure of Functioning in MCI and Early AD1R44AG058345-01 | ATKINS, ALEXANDRA STRICKLAND | VERASCI, LLC, NC | $215,399 | ZRG1 |
| 2017 | Development of a robust quantitative systems pharmacology model of amyloid beta and tau pathways for clinical trial design and decision making in Alzheimer’s Disease and Dementia.1R44AG058411-01 | GRUENBAUM, LORE | APPLIED BIOMATH, LLC, MA | $188,363 | ZRG1 |
| 2017 | Real-time video monitoring of falls in memory-care facilities for individuals with Alzheimer's and related dementias1R43AG058354-01 | BAYEN, ALEXANDRENETSCHER, GEORGEXIONG, GLEN | SAFELYYOU, INC., CA | $150,000 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.